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RESEARCH ARTICLE Open Access
Prospective study of recovery from copperhead
snake envenomation: an observational study
Eric J Lavonas1,2* and Charles J Gerardo3 for the Copperhead Snakebite Recovery Outcome Group
Abstract
Background: Although much is known about signs, symptoms, and management in the acute phase of crotaline
snake envenomation, little is known about signs, symptoms, function, and quality of life during the recovery phase.
The purpose of this observational pilot investigation is to evaluate the utility of several clinical outcome instruments
in the setting of copperhead snakebite, and to characterize the clinical course of recovery.
Methods: This is a multi-center prospective, open-label, observational study of patients envenomated by copperhead
snakes. We administered the Disabilities of the Arm, Shoulder, and Hand (DASH), Lower Extremity Functional Scale
(LEFS), Patient-Specific Functional Scale (PSFS), Work Productivity and Ability Impairment: Special Health Problem
(WPAI: SHP), Patients’ Global Impression of Change (PGIC), Patient’s Global Assessment of Recovery (PGAR), and
SF-36 instruments, obtained numeric pain rating scales, and measured grip strength, walking speed, and swelling
prior to hospital discharge and 3, 7, 14, 21, and 28 days after envenomation.
Results: 20 subjects were enrolled; none were lost to follow-up. Most (80%) had moderate severity swelling, and
most (75%) received antivenom. Across the broad range of measures, abnormalities of pain, swelling, impairments
of physical and role function, and quality of life persisted for 7–14 days in most subjects. Validated self-reported
outcome measures, such as the DASH, LEFS, PSFS, PGIC, SF-36, and the daily activities impairment portion of the
WPAI: SHP were more responsive than measurements of swelling or walking speed. Data quality issues limited
the utility of the work impairment portion of the WPAI: SHP. Residual signs, symptoms, and impairment in some
subjects lasted through the 28-day study period. The study design precluded any assessment of the effectiveness
of antivenom.
Conclusions: Signs, symptoms, impaired function, and decreased quality of life typically last 7 – 14 days after
copperhead envenomation. Several tools appear responsive and useful in studying recovery from pit viper
envenomation.
Trial registration: ClinicalTrials.gov NCT01651299
Keywords: Agkistrodon, Antivenins, Crotalid venoms, Disability evaluation, Lower extremity, Quality of Life,
Recovery of function, Snake bites, Upper extremity
Background
Approximately 8,500 people are treated in emergency
departments (EDs) in the United States (US) each year
for evaluation of potentially venomous snakebite [1].
The vast majority of venomous bites are caused by cro-
taline snakes (pit vipers: rattlesnakes, cottonmouths,
and copperheads). Among envenomation cases for
which the species is known, approximately 51% are due
to copperheads (Agkistrodon contortrix) [2]. However,
only rattlesnake and cottonmouth victims were enrolled
in the premarketing trials for the current US pit viper
antivenom, Crotalidae Polyvalent Immune Fab (Ovine)
(CroFab®, BTG International, West Conshohocken, PA;
hereafter, FabAV) [3,4]. Data from the US National Poison
Data System suggest that antivenom use is much less com-
mon in copperhead victims (36% of patients treated in
2007 received antivenom) than in rattlesnake victims (55%)
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[5]. This is likely because copperhead envenomation pa-
tients rarely develop life-threatening systemic effects, such
as hypotension and hematologic abnormalities that are
common in rattlesnake envenomation [6-8]. The propor-
tion of copperhead victims receiving antivenom has in-
creased significantly, from 21% in 2001 to 36% in 2007,
with significant regional variations [5].
Even though copperhead envenomation is rarely fatal,
virtually all patients experience pain and swelling of the
envenomated limb [6,8-11]. Most patients recover and re-
sume activities of daily living within 2–4 weeks, but in a
minority of cases, residual symptoms last a year or more
[10-12]. Persistent limb dysfunction has been described in
patients managed with and without antivenom [10-12].
Although antivenom administration clearly halts the
progression of local tissue injury from snake envenom-
ation, it is unclear whether antivenom reduces the dur-
ation or severity of lasting limb impairment [6-8,10]. The
only previous investigation was a small clinical trial that
was terminated early and was underpowered to detect any
differences between patients receiving antivenom or pla-
cebo [10]. This question is important because FabAV is
very expensive; an initial dose of 4 to 6 vials can cost a
hospital approximately $US 12,000 – 21,000.
While several assessment tools exist to measure limb
function, impairment, and quality of life following limb
trauma and limb surgery, none of these tools have been
validated in the setting of snakebites. The ability to per-
form valid and reliable serial assessments is a prerequis-
ite to a clinical trial evaluating the effect of antivenom
administration on recovery from copperhead snakebite.
The purpose of this pilot investigation is to evaluate
the utility of several clinical outcome instruments in the
setting of copperhead snakebites. A secondary objective
is to characterize the clinical course of signs, symptoms,
and impairment during the recovery phase of copper-
head snakebite managed with and without FabAV.
Methods
Study design and setting
This is a multi-center, prospective observational study
conducted at 11 clinical sites across the southeastern
US. All treatment provided, including the decision to ad-
minister or not administer antivenom, was at the discre-
tion of the treating physician. Subjects were enrolled in
the emergency department, followed through their initial
hospital encounter, and returned for outpatient assess-
ments performed 3, 7, 14, 21, and 28 days after
envenomation.
Participants
Patients were eligible for inclusion if they were adults
(aged 18 years or older) who were envenomated by a
copperhead on an extremity, distal to the elbow or knee.
Snake species identification was established by one of
four means: snake or photograph of the snake brought
to the ED, envenomation that occurred in an area where
copperheads are the only endemic pit viper, envenom-
ation by a captive copperhead, or the patient correctly
identifying a copperhead from an array of snake photo-
graphs. Although clinical evidence of venom effect (limb
swelling and/or tenderness) was required, the venom ef-
fects did not need to be progressing at the time of en-
rollment. Patients must have presented for their initial
episode of care within 24 hours of envenomation, and
enrollment had to be completed within 48 hours of en-
venomation and prior to discharge from the ED or hos-
pital. Prisoners and women who were pregnant or
breastfeeding were excluded. In addition, patients were
excluded if they were unable to read and comprehend
the consent document or written assessment tools or if
they had a distracting injury or other condition that
would limit the ability to make a reliable self-report of
functionality status based solely on the condition of
interest. Patients who sustained a previous snake en-
venomation to any body area or a previous injury to
the envenomated limb within 30 days prior to enroll-
ment were also excluded. Study materials were pre-
pared in English and Spanish, with back-translation
used to verify accuracy of Spanish-language assessment
materials.
Data collection
Following screening, enrollment, and exclusion of preg-
nancy, each subject provided demographic information,
past medical and medication histories, history of en-
venomation, information about usual occupation and
left-hand or right-hand dominance. A complete physical
examination was also performed. Data about the initial
hospital encounter, including date and time of arrival,
maximal extent of swelling, antivenom administration,
laboratory test results, and adverse events were recorded
by study personnel at the time of care, and missing in-
formation was obtained from the hospital record.
Formal study assessments were performed prior to
discharge from the initial ED/hospital encounter and
then 3 (+/−1) days and 7, 14, 21, and 28 (+/− 3) days
after envenomation. At each study assessment, subjects
were asked to provide a detailed history of all medica-
tions taken since the previous study visit, and a focused
physical assessment was performed to evaluate the ex-
tent of swelling and the presence or absence of necrotic
tissue. The results of any laboratory studies were cap-
tured, and the subject was questioned about potential
adverse events from treatment or study participation.
Following this data collection, study-specific assess-
ments were performed, as detailed below. A priori
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procedures were established to deal with subjects who
were unable to attend scheduled follow-up visits as de-
tailed below.
Assessment instruments
Study-specific assessments were performed in the fol-
lowing order:
Analgesic use
Using data from the a standardized list of medications
supplemented by focused questions as needed, study
personnel categorized the subject’s analgesic use in the
previous 24 hours as: no analgesic; non-prescription an-
algesics only; prescription, non-opioid analgesics; opioid
analgesics (including tramadol and opioid combination
products). The results were analyzed as ordinal data.
Recovery: patient global assessment of recovery
This is a single item question that is administered ver-
bally. The question is, “Have you completely recovered
from your snakebite?” The purpose of this instrument
was to test whether response to this single question
was a useful proxy for more involved assessments of
recovery.
Pain: numeric pain rating scale
This is a single item question administered verbally. The
question is, “Please rate your pain on a scale of 0 to 10,
with 0 being no pain and 10 being worst possible pain.”
Ordinal (Likert) scales are well-correlated with visual
analog scale scores for muscle soreness and are more
easily administered [13].
Swelling: numeric swelling scale
This is a single item question administered verbally. The
question is, “Please rate your swelling on a scale of 0 to
Screened
22 Patients
Enrolled
20 Subjects
Not enrolled
Unwilling / unable to 
complete follow-up 
assessments:
2 Patients
Completed 
Study
20 Subjects
Drop-Outs
0 subjects
Figure 1 Participant Flow.
Table 1 Study subjects
Characteristic Number of subjects
(n, %)
Enrolled subjects 20 (100%)
Completed 28 days of study participation 20 (100%)
Sex
Male (n, %) 10 (50%)
Age
Age (years) (median, range) 37 (19–76)
Aged≥ 65 years 3 (15%)
Race and ethnicity
White race 16 (80%)
Black or African American race 4 (20%)
Hispanic or Latino ethnicity 0 (0%)
Study site
Duke University Medical Center
(Durham, NC)
12 (60%)
East Carolina University/Vidant
Medical Center (Greenville, NC)
3 (15%)
St. Joseph Regional Health Center
(Bryan, TX)
3 (15%)
Scott and White Memorial Hospital
(Temple, TX)
1 (5%)
University of Virginia (Charlottesville, VA) 1 (5%)
Envenomation location
Upper extremity 10 (50%)
Envenomation severity at enrollment
Mild 1 (5%)
Moderate 16 (80%)
Severe 3 (15%)
Treatment
Treated with antivenom 15 (75%)
Total antivenom dose (vials) (among
patients receiving) (median, range)
14 (4, 24)
Duration of Hospitalization (hours)
(median, range)
35.5 (5, 49)
For the purposes of this study, envenomation severity was determined based
on the number of major joints (wrist, elbow, ankle, knee) involved in limb
swelling. Swelling that did not cross any major joints (e.g. confined to the
hand) was defined as “mild.” Swelling that crossed one major joint (e.g.
involving the hand and forearm) was defined as “moderate,” and swelling that
crossed two major joints (e.g. from hand to upper arm) was defined
as “severe”.
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10, with 0 being no swelling and 10 being very severe
swelling.” The purpose of this instrument was to test
whether response to this single question was a useful
proxy for objective assessments of swelling.
Resumption of work, school, or usual activities of daily
living (ADLs)
This is a two-stage question that is administered ver-
bally. The question is, “Have you returned to full duties
or participation at [state subject’s occupation]?” If the
subject answered in the affirmative, then the answer to a
follow-up question, “What was the first day that you
returned to full duties or participation at [occupation]?”
was recorded. The purpose of this instrument was to test
whether response to this single instrument was a useful
proxy for more involved assessments of ability to per-
form work or ADLs. This instrument was first adminis-
tered on the Day 3 assessment.
Recovery: Patient’s Global Impression of Change (PGIC)
This is a two-item assessment tool that uses separate or-
dinal scales to assess change “since beginning treatment
at this clinic” [14]. The first item, a 7-item Likert scale,
anchored at 1 (“No change (or condition has gotten
worse)”), is used to assess improvement. The second
item is an 11-item Likert scale, anchored at 5 (“No
change”), where 0 is “Much better” and 10 is “Much
worse”, is used to assess change overall. The Patient’s
Global Impression of Change is widely used to define
clinically meaningful improvement in orthopedic and
Table 2 Analgesic use: Overall Study Results
Day 3 Day 7 Day 14 Day 21 Day 28
n % n % n % n % n %
No analgesic 9/20 45 10/20 50 14/19 74 16/20 80 16/20 80
Non-prescription analgesic 1/20 5 3/20 15 1/19 5 2/20 10 4/20 20
Prescription analgesic, non-opioid 1/20 5 1/20 5 1/19 5 0/20 0 0/20 0
Opioid analgesic 9/20 45 6/20 30 3/19 16 2/20 10 0/20 0
Classification of the strongest type of medication used by study subjects to treat snakebite-related pain in the 24 hours prior to each scheduled study assessment.
The day of envenomation is Day 0.
Figure 2 Analgesic Use: Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV n = 15; No FabAV n = 5. B:
Subgroup size: Mild n = 1, Moderate n = 16, Severe n = 3. C: Subgroup size: Upper extremity (UE) n = 10, Lower extremity (LE) n = 10.
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other pain studies. This instrument was first adminis-
tered on the Day 3 assessment.
Impairment: Disabilities of the Arm, Shoulder, and Hand
(DASH) or Lower Extremity Functional Scale (LEFS)
Separate validated questionnaires were used to assess
upper extremity and lower extremity impairment.
The Disabilities of the Arm, Shoulder, and Hand (DASH)
Outcome Measure was used for subjects with upper ex-
tremity envenomation [15,16]. The DASH is a 30-item self-
administered questionnaire designed to assess impairment
due to upper extremity injuries. The DASH has a standard
period of recall of one week. Minor modifications were
made to this tool at two time points. On the first assess-
ment (just prior to hospital discharge), the tool was modi-
fied to collect subject recall of his or her baseline status
prior to envenomation; in order to accomplish this, the
recall period was adjusted to, “In the week prior to your
snakebite…” On the Day 3 assessment, the tool was modi-
fied to collect information about the time period from hos-
pital discharge to that assessment; the recall period was
therefore adjusted to, “Since you were discharged from the
hospital…” Although these modifications have not been val-
idated, they were used in a previous trial with apparently
good performance [10]. For the day 7, 14, 21, and 28 assess-
ments, the standard recall period (“in the last week…”) was
used. The range of possible scores is 0 – 100, and a higher
score indicates more disability.
Subjects with lower extremity envenomation completed
the Lower Extremity Functional Scale (LEFS), a widely-
accepted, 20-item questionnaire that tests impairment due
to lower extremity injuries [17]. The standard recall period
for the LEFS is “today.” As with the DASH, the assessment
made just prior to hospital discharge was modified to
Table 3 Patient’s Global Assessment of Recovery (PGAR): Overall Study Results
Discharge Day 3 Day 7 Day 14 Day 21 Day 28
n % n % n % n % n % n %
Subjects reporting complete recovery 1/20 5 2/20 10 4/20 20 6/20 30 12/20 60 14/20 70
Patients’ response to the question, “Have you completely recovered from your snakebite?” A larger number indicates a greater proportion of patients recovered.
The day of envenomation is Day 0.
Figure 3 Patient Global Assessment of Recovery (PGAR): Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV n =
15; No FabAV n = 5. B: Subgroup size: Mild n = 1, Moderate n = 16, Severe n = 3. C: Subgroup size: Upper extremity n = 10, Lower extremity n = 10.
Lavonas and Gerardo BMC Emergency Medicine  (2015) 15:9 Page 5 of 21
collect a pre-injury baseline (“In the day prior to your
snakebite…”). The range of possible scores is 0 – 80; the
minimal clinically important difference is 9 scale points,
and a higher score indicates less disability.
Global Function: Patient-Specific Functional Scale (PSFS)
This is a three-item instrument, administered verbally, that
is used to evaluate whether a health condition impacts a pa-
tient’s ability to perform activities that are important to
him/her. On the initial assessment, the patient is asked to
identify “up to three important activities that you are unable
to do or are having difficulty with as a result of your (snake-
bite).” The patient then provides a rating for each item, on
an 11-point ordinal scale ranging from 0 (“unable to per-
form activity”) to 10 (“able to perform activity at the same
level as before the injury or problem”). During reassess-
ments, the subject is prompted to re-rate the same three
activities. The PSFS has been shown to be a sensitive, reli-
able, and responsive measure of impairment due to a wide
variety of orthopedic conditions [18,19]. By design, the
PSFS collects patient-oriented outcomes. Both 5-activity
and 3-activity versions of this instrument have been de-
scribed; because test performance is similar, we used the
more parsimonious (3-activity) version. An average of the
three “important activity” scores was used for calculations.
This instrument was first administered on the Day 3
assessment.
Health-related quality of life: 36-item short-form health
survey (SF-36®, v2 Acute version)
The Medical Outcomes Study 36-item Short-Form Health
Survey, version 2 (SF-36®, v2 Acute version) is a self-
administered questionnaire designed to evaluate overall
health status [20]. Each item is an ordinal scale with 3 to 6
Table 4 Numeric Pain Rating Scale (NPRS): Overall Study Results
Discharge Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range Median Range
Score 4 0, 10 2 0, 9 2.5 0, 8 0.5 0, 5 0 0, 4 0 0, 2
Subjects’ self-reported pain, ordinal scale ranging from 0 (“no pain”) to 10 (“worst possible pain”) [13]. Data based on 20 subjects. A larger number indicates more
pain. The day of envenomation is Day 0.
Figure 4 Numeric Pain Rating Scale (NPRS): Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV n = 15;
No FabAV n = 5. B: Subgroup size: Mild n = 1, Moderate n = 16, Severe n = 3. C: Subgroup size: Upper extremity n = 10, Lower extremity n = 10.
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possible scores, weighted to produce overall score ranges of
0 – 100. Weighted averages are then used to summarize
items within domains to create a Mental Component Scale
(MCS) and Physical Component Scale (PCS). We utilized
the acute version of the instrument, which has a period of
recall of one week. As with the DASH and LEFS, during
the time of discharge study visit we collected a recall-based
estimation of the subject’s pre-envenomation baseline. Be-
cause of the look-back period, we did not collect this meas-
ure at the Day 3 assessment.
Ability to Work: Work Productivity and Ability Impairment:
Special Health Problem, version 2 (WPAI: SHP)
This is a 6-item self-administered questionnaire de-
signed to evaluate work limitation due to a specific
health issue [21]. The WPAI: SHP is designed to cap-
ture both lost work time (“absenteeism”) and low work
output (“presenteeism”). We used version 2 of this in-
strument, which consists of one yes/no question (“Are
you currently employed (working for pay)?”), three
questions about the number of hours of work / missed
work, and one question that asks about productivity
while at work. This final question collects responses
on an 11-point ordinal scale, anchored at 0 (“Snake-
bite had no effect on my work”) and 10 (“Snakebite
completely prevented me from working”). These five
questions are used to calculate a percent of impair-
ment from baseline work productivity. One additional
question asks about ability to perform regular daily ac-
tivities, other than work at a job, and ranged from 0
Table 5 Numeric Swelling Scale (NSS): Overall Study Results
Discharge Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range Median Range
Score 6.5 2, 10 3 0, 9 1 0, 9 0.5 0, 4 0 0, 3 0 0, 3
Subjects’ self-reported swelling, ordinal scale ranging from 0 (“no swelling”) to 10 (“very severe swelling”). A larger number represents more swelling. Data based
on 20 subjects. The day of envenomation is Day 0.
Figure 5 Numeric Swelling Scale (NSS): Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV n = 15; No FabAV n
= 5. B: Subgroup size: Mild n = 1, Moderate n = 16, Severe n = 3. C: Subgroup size: Upper extremity n = 10, Lower extremity n = 10.
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(“Snakebite had no effect on my daily activities”) to 10
(“Snakebite completely prevented me from doing my
daily activities”). Although this question is collected
on an ordinal scale, the results are communicated as a
percent [22]. The WPAI: SHP was first administered
on the Day 3 assessment.
Swelling: Figure-of-eight measurement
Objective measurements of swelling were obtained by using
the combined circumference of the wrist/hand or foot/
ankle, as appropriate for upper extremity or lower extrem-
ity envenomations. Investigators were trained to take
figure-of-eight measurements using a ¼ inch (~6.5 mm)
wide plastic retractable tape measure and standardized
technique. Dressings more than 1 mm thick were removed
prior to measurements. Measurements were recorded to
the nearest 0.1 cm, and the median of three measurements
was used for calculations. Figure-of-eight measurements
have been shown to correlate well with limb swelling mea-
surements obtained by more cumbersome methods, such
as water volumetry, in both the upper and lower extremity
[23-26]. Figure-of-eight measurements were performed
prior to grip strength or walking speed testing.
Function: Grip strength or walking speed
To objectively measure hand function, patients with upper
extremity envenomation performed grip strength measure-
ments [27,28]. Three measurements of grip strength were
performed using a JAMAR® 5030 J1 Hydraulic Hand Dyna-
mometer (Sammons Preston Roylan, Chicago, IL, USA),
and the greatest value, measured in kilograms, was
recorded.
Table 6 Return to work, school, or usual Activities of Daily Living (ADLs): Overall Study Results
Day 3 Day 7 Day 14 Day 21 Day 28
n % n % n % n % n %
Subjects returned to usual activities 3/20 15 8/20 40 14/20 70 18/20 90 19/20 95
Patients’ self-reported answer to the question, “Have you returned to full duties or participation at [state subject’s occupation]?” A larger number indicates a greater portion of
patients who have returned to usual activities. The day of envenomation is Day 0.
Figure 6 Return to Work, School, or Usual Activities of Daily Living (ADLs): Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine).
Subgroup size: FabAV n = 15; No FabAV n = 5. B: Subgroup size: Mild n = 1, Moderate n = 16, Severe n = 3. C: Subgroup size: Upper extremity
n = 10, Lower extremity n = 10.
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To objectively measure lower extremity function, patients
with lower extremity envenomation performed walking
speed tests [29,30]. Beginning from standing, subjects
walked 7.62 meters (25 feet) on indoor level ground as
quickly, but safely, as possible without running. Two trials
were performed, and the faster time was recorded. Subjects
who could not complete the task without assistance or de-
vices were not tested, and the maximum allowed time
(180 seconds) was recorded.
Procedure for missed study assessments
If a subject missed a study visit, study personnel attempted
to contact the subject by phone to arrange and reschedule
a study visit within the permissible time window. If the pa-
tient refused or an in-person visit could not be arranged for
some other reason, study personnel attempted to obtain all
data for that visit by telephone, except figure-of-eight swell-
ing measurements, grip strength, and/or walking speed.
Subjects who missed 3 or more designated study visits were
Table 7 Patient’s Global Impression of Change (PGIC): Overall Study Results
Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range
Scale One score 5 1, 7 6 2, 7 6 2, 7 7 1, 7 7 1, 7
Scale Two score 4 0, 9 2 0, 4 1 0, 6 0 0, 5 0 0, 9
Both scores assess the patient’s self-report of change, “since beginning treatment at this clinic” [14]. Scale one is a 7-item Likert scale, ranging from 1 (“No change
(or condition has gotten worse)”) to 7 (“A great deal better, and a considerable improvement that has made all the difference”). Scale two is an 11-item Likert
scale, ranging from 0 (“Much better”) to 10 (“Much worse”). Therefore, higher scores on scale one indicate more recovery and higher scores on scale two indicate
less recovery. Data based on 20 subjects except for Day 3 (n =19). The day of envenomation is Day 0. One subject provided an anomalous result to the Scale Two
score on Day 28 (see text).
Figure 7 Patient’s Global Impression of Change (PGIC): Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV
n = 15; No FabAV n = 5. Missing data from one FabAV subject on Day 3 and one No FabAV subject on Day 14. B: Subgroup size: Mild n = 1, Moderate
n = 16, Severe n = 3. Missing data from 1 Severe subject on Day 3 and one Moderate subject on Day 14. C: Subgroup size: Upper extremity n = 10,
Lower extremity n = 10. Missing data from one Lower Extremity subject on Day 3 and one Upper Extremity subject on Day 14.
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removed from subsequent participation the study, except
for adverse event follow-up.
Safety assessments
At each visit, all adverse events (AEs) observed by the in-
vestigator or study personnel or reported by the patient
were recorded in the medical record and entered into an
adverse event reporting sheet. For each AE, the site inves-
tigator recorded a description of the event, seriousness,
onset and stop dates for the event, severity, relationship to
study participation, relationship to FabAV administration,
action taken, and outcome. An AE was defined as serious
using standard criteria, and both serious and non-serious
AEs were reported to the FDA and IRBs in accordance
with established requirements [31]. A secondary review of
each reported AE was performed by the study safety
monitor, who also reviewed the list of all medications used
by subjects after enrollment and/or FabAV administration
to look for AEs that may not have been reported by site
investigators.
Analysis
Data handling
Data were captured by trained study personnel using struc-
tured worksheets and entered into a Research Electronic
Data Capture System (REDCap™) database.(version 5.0.015;
REDCap Consortium and Vanderbilt University, Nashville,
TN) [32]. Following data validation and error checks, the
final database was exported to SAS (version 9.3; SAS Insti-
tute, Cary, NC) for analysis.
Sample size
Prior to this study, no evaluable data existed for limb
recovery following crotaline envenomation. Formal power
calculation was neither possible nor appropriate to the
study’s intended purpose. Furthermore, logistical and
budgetary considerations limited recruitment to a max-
imum of 11 study sites and half a snakebite “season”,
leading to a target sample size of 20 evaluable subjects.
Because of the observational and exploratory study de-
sign, no prespecified hypothesis testing and no study
termination criteria for efficacy, futility, or safety were
determined, and no interim analyses were planned. Ad-
justment for multiple statistical comparisons was not
required because hypothesis testing was not performed.
Analysis plan
All analyses were performed by trained statisticians using
SAS (version 9.3; SAS Institute, Cary, NC). Except where
explicitly noted, all statistical analyses were planned a
priori.
Hypothesis testing was neither planned nor performed.
Because most data were either ordinal scale and/or skewed,
data are summarized descriptively using median and range.
Recovery was defined as return to the patient’s own
baseline on the DASH, LEFS, and SF-36® MCS and PCS
instruments, as assessed on the “look-back” questioning
Table 8 Disabilities of the Arm, Shoulder, and Hand (DASH) score: Overall Study Results
Pre-Envenomation Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range Median Range
Score 2.1 0.0, 11.7 28.3 0.0, 71.7 7.1 0.0, 63.3 6.3 0.0, 30.8 1.7 0.0, 20.8 0.8 0.0, 12.5
Score on the Disabilities of the Arm, Shoulder, and Hand (DASH) outcome measure [15,16]. The range of possible scores is 0 – 100. Higher scores indicate more
disability. Evaluation limited to subjects with upper extremity envenomation (n = 10). The day of envenomation is Day 0. Use of “look back” questioning to
establish pre-injury baseline has not been previously validated for the DASH.
Figure 8 Disabilities of the Arm, Shoulder, and Hand (DASH) Scores: Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine).
Subgroup size: FabAV n = 6; No FabAV n = 4. B: Subgroup size: Mild n = 1; Moderate n = 8; Severe n = 1.
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performed prior to hospital discharge, and to no impair-
ment on the WPAI: SHP instrument. A pre-planned sensi-
tivity analysis was performed defining recovery for the
DASH as return to the US population mean score (10.1)
[33]. For time-dependent variables (recovery on the
DASH, LEFS, SF-36® MCS/PCS, and WPAI: SHP instru-
ments; return to work), time-to-event analytic methods
were used to estimate median time to achieve the recovery
endpoint. Return to work was assessed in the actual num-
bers of days to return while all other assessments are
assessed at the day 3, 7, 14, 21, and 28 study assessments,
when collected.
Subgroup analyses
For each assessment tool and time point, a primary analysis
is reported for all subjects with data, and pre-planned sub-
group analyses are presented for: (1) patients who did and
did not receive FabAV; (2) patients with initially mild, mod-
erate, and severe envenomation; and (3) patients with upper
extremity and lower extremity envenomation. For the pur-
poses of this study, envenomation severity was determined
solely based on the number of major joints (wrist, elbow,
ankle, knee) involved in limb swelling. Swelling that did not
cross any major joints (e.g. confined to the hand) was
defined as “mild.” Swelling that crossed one major joint
(e.g. involving the hand and forearm) was defined as
“moderate,” and swelling that crossed two major joints
(e.g. from hand to upper arm) was defined as “severe.”
Handling of missing data; sensitivity analysis
The primary analysis was performed with the assumption
that data are missing at random therefore missing data
were not imputed for this primary analysis. Sensitivity ana-
lyses were conducted using linear interpolation to impute
data points for which previous and subsequent observations
were available, and Last Observation Carried Forward
(LOCF) when these points were not available. When the
data-point from the first assessment time-point was missing
it was left as missing as neither LOCF nor linear interpola-
tions are possible. Missing data for subjects who failed to
complete 3 or more study visits were not imputed.
Correlations between outcome measures
In order to determine which outcome measures provided
similar data, we calculated Spearman rank correlations be-
tween the numeric scores on each item.
Human subjects protection
This study was conducted in accordance with the
World Medical Association Declaration of Helsinki
(1996) and current Good Clinical Practice in accord-
ance with International Conference on Harmonisation
standards. All study procedures were reviewed and ap-
proved by the Western Institutional Review Board
(WIRB) and by the IRB responsible for each clinical
site. The activities of the coordinating center were ap-
proved by the Colorado Multiple IRB (COMIRB).
Table 9 Lower Extremity Functional Scale (LEFS): Overall Study Results
Pre-Envenomation Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range Median Range
Score 79 12, 80 17 5, 31 38 8, 80 67.5 23, 80 72 60, 80 80 65, 80
Score on the Lower Extremity Functional Scale (LEFS) outcome measure [17]. The range of possible scores is 0 – 80. Higher scores indicate less disability. Evaluation limited to
subjects with lower extremity envenomation (n = 10) except for Day 21 (n = 9). The day of envenomation is Day 0. Use of “look back” questioning to establish
pre-injury baseline has not been previously validated for the LEFS.
Figure 9 Lower Extremity Functional Scale (LEFS) Scores: Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup
size: FabAV n = 9; No FabAV n = 1. Missing data from one FabAV subject on Day 21. B: Subgroup size: Mild n = 0, Moderate n = 8, Severe n =
2. Missing data from one Severe subject on Day 21.
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Written informed consent was obtained from all sub-
jects prior to participation.
Control of data and decision to publish
Duplicate copies of all audited data were maintained at
the Rocky Mountain Poison and Drug Center and BTG
International, Inc., and statisticians from both organiza-
tions had full access to all data. The statistical analysis
plan was determined a priori and agreed-upon by both
organizations. The trial was registered on www.Clinical
Trials.gov as protocol NCT01651299. A written commit-
ment to publish study results within 18 months of study
completion was established in the initial study protocol;
BTG International retained a 60-day right to review the
manuscript for proprietary information. The choice of
journal was made jointly between the corresponding au-
thor and BTG International.
Results
Subject enrollment
A total of 22 subjects were screened and 20 were enrolled
in the study. Two potential subjects were excluded because
they were unwilling or unable to complete follow-up assess-
ments; no subjects were excluded because of distracting in-
juries or other comorbidities that would limit the validity of
assessments. No subjects were lost to follow-up, though in
one subject the Day 28 assessment was performed outside
the allowed (+/− 3 day) window. Characteristics of study
subjects are presented in Table 1, and subject enrollment
flow appears in Figure 1. Half of subjects were male, most
Table 10 Patient-Specific Functional Scale (PSFS): Overall Study Results
Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range
Score 2.2 0, 10 6.8 0, 10 9.3 0, 10 10.0 0, 10 10.0 0, 10
Score on the Patient-Specific Functional Scale outcome measure [17]. The average of up to 3 specific activity scores was recorded, and the range of possible scores
is 0 – 10. Higher scores indicate less impairment. Data based on 20 subjects. The day of envenomation is Day 0.
Figure 10 Patient-Specific Functional Scale (PSFS): Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV n =
15; No FabAV n = 5. B: Subgroup size: Mild n = 1, Moderate n = 16, Severe n = 3. C: Subgroup size: Upper extremity n = 10, Lower extremity n = 10.
Lavonas and Gerardo BMC Emergency Medicine  (2015) 15:9 Page 12 of 21
were non-Hispanic whites (80%), and the median age was
37 years. Upper extremity and lower extremity envenoma-
tions were evenly represented. Most subjects (80%) had
moderate severity envenomation, and most (75%) received
FabAV. Twelve subjects (60%) were enrolled at a single
study site; four sites enrolled 1 – 3 subjects each, and
six sites enrolled no subjects
As expected, patients with more severe envenomation
were more likely to receive FabAV therapy than patients
with lesser severity envenomation: 3/3 (100%) of patients
with severe envenomation received antivenom, com-
pared with 12/16 (80%) of those with moderate severity
envenomation. The one patient with mild severity en-
venomation did not receive FabAV. Imbalance was also
seen between FabAV use and bite location: 9/10 (90%) of
patients with lower extremity envenomation received
FabAV, compared with 6/10 (60%) of those bitten on the
upper extremity.
Recovery from copperhead envenomation
Analgesic use
Table 2 shows analgesic use for all time periods, and
Figure 2A–C show analgesic use subgroup analyses
based on FabAV therapy, envenomation severity, and
envenomation site. Half of patients no longer required
analgesics at the Day 7 assessment, and no patient re-
quired opioid analgesics by Day 28.
Recovery
Table 3 shows the patients’ global assessment of recovery
for all time periods, and Figure 3A–C show these data
by therapy, severity, and site. Fourteen of 20 subjects
(70%) considered themselves to be fully recovered by the
Day 28 assessment.
Self-reported pain and swelling
Table 4 shows the patients’ self-reported pain at each
study visit, and Figure 4A–C show subgroup results. In
general, patients reported little pain at any time point,
though patients with severe swelling and lower extrem-
ity envenomation seemed to fare worse on this measure
for the first 2 weeks after envenomation. Table 5 and
Figure 5A–C show patients’ self-reported swelling.
Interestingly, there was little reported difference on this
measure between subjects with mild, moderate, and se-
vere initial swelling. All patients perceived swelling to
be minimal by the Day 7 visit.
Return to work, school, or usual activities of daily living
(ADLs)
Table 6 and Figure 6A–C show patients’ self-reported re-
turn to full participation in their usual activities of daily
living. The median time to return to full participation
was 11 days (range: 2 to >28 days), with 1/20 subjects
(5%) unable to return on Day 28.
Patient’s Global Impression of Change (PGIC)
Table 7 and Figure 7A–C show the patients’ self-reported
impression of change. Patients’ perceived improvement
between initiation of care and the Day 3 assessment, and
most patients perceived a great deal of improvement by
Day 14. Subgroup results on the PGIC Scale Two score
(not shown) were similar to those on the Scale One score.
One subject was provided an anomalous result on the
Scale Two score on the Day 28 assessment. Despite im-
proving scores on the PSFS (improvement from 0 to 7.33),
LEFS (5 to 65), SF-36 PCS (22.5 to 51.4), and PGIC Scale
one score (2 to 6), he reported being “much worse” (score
9) on the PGIC Scale Two score. This is also inconsistent
with his prior responses on PGIC Scale Two question (ser-
ial scores of 9, 4, 4, and 2), which showed improvement
consistent with that reported on the other instruments.
Impairment: DASH and LEFS
Table 8 and Figure 8A–B show impairment for patients
with upper extremity envenomation. Patients reported
marked impairment at the Day 3 assessment and
marked improvement thereafter. The median time for a
subject to return to his/her pre-envenomation baseline
was 21 days (range: 3 to >28 days), and at the end of
the 28-day study period, 2/10 (20%) of patients had not
recovered to their own baseline. Data for the US popu-
lation are available for the DASH, and analysis showed
a median time of 7 days (range: 3 to >28 days) to
Table 11 36-Item Short Form Health Survey (SF-36®, v2 Acute version): Overall Study Results
Pre-Envenomation Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range
SF-36 Physical Component
Summary score
56.0 23.9, 60.2 45.1 18.3, 60.5 51.4 22.8, 60.5 58.3 38.0, 60.3 58.3 47.7, 60.4
SF-36 Mental Component
Summary score
56.6 43.5, 68.8 55.0 28.9, 65.8 58.3 43.0, 63.8 56.5 39.5, 64.4 57.2 47.6, 61.9
Scores on the SF-36®, v2 (Acute Version) outcome measure Physical Component Summary and Mental Component Summary measures [20]. The range of possible
scores on all measures is 0–100. Higher scores indicate better quality of life. Data based on 20 subjects. The day of envenomation is Day 0. Use of “look back”
questioning to establish pre-injury baseline has not been previously validated for the SF-36.
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Table 12 Impairment at daily activities outside of work: Overall Study Results
Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range
Percent Daily Activities Impairment 80 0, 100 60 0, 100 10 0, 80 0 0, 40 0 0, 30
Percent impairment of regular daily activities other than work is calculated by taking self-reported impairment on item 6 of the Work Productivity and Ability Impairment:
Special Health Problem instrument. This is an 11-item ordinal scale, ranging from 0 “(Snakebite had no effect on my daily activities”) to 10 (“Snakebite completely prevented
me from doing my daily activities”), multiplied by 10. Higher scores indicate more impairment. The day of envenomation is Day 0.
Figure 11 Quality of Life, 36-item Short Form Health Survey (SF-36®, v2 Acute version) Physical Component Scale and Mental Component Scale Scores:
Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV n = 15; No FabAV n = 5. B: Subgroup size: Mild
n = 1, Moderate n = 16, Severe n = 3. C: Subgroup size: Upper extremity n = 10, Lower extremity n = 10. D: FabAV: Crotaline Polyvalent Immune Fab
(ovine). Subgroup size: FabAV n = 15; No FabAV n = 5. E: Subgroup size: Mild n = 1, Moderate n = 16, Severe n = 3. F: Subgroup size: Upper
extremity n = 10, Lower extremity n = 10.
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recover to the US population mean score on the DASH
instrument.
Patients with lower extremity envenomation (Table 9
and Figure 9A–B) showed more gradual recovery, with a
median time to recover to personal baseline of 14 days
(range: 3 to >28 days). At the end of the 28-day study
period, 2/10 (20%) of patients had not recovered to their
own baseline. Normative data about the US population
are not available for the LEFS.
Function in activities important to the patient (PSFS)
Table 10 and Figure 10A–C show the patients’ reported
ability to participate in activities that are self- identified
as important by the subject. Patients reported a great
Figure 12 Daily Activities Impairment: Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV n = 15; No FabAV
n = 5. B: Subgroup size: Mild n = 1, Moderate n = 16, Severe n = 3. C: Subgroup size: Upper extremity n = 10, Lower extremity n = 10.
Table 13 Figure-of-eight swelling measurements: Overall Study Results
Discharge Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range Median Range
Upper extremity measurement
(cm)
47.0 38.0,
51.8
46.7 38.0,
51.6
45.0 37.5,
50.5
45.0 37.5,
51.5
45.5 37.5,
50.0
46.5 37.2,
50.3
Upper extremity, difference
from measurement at hospital
discharge (cm)
– – −0.9 −3.5,
0.0
−2.0 −3.7,
0.0
−2.0 −3.6,
+0.1
−2.8 −4.0,
0.5
−1.3 −3.8,
+1.0
Lower extremity measurement
(cm)
54.5 49.3,
61.0
55.8 49.0,
61.1
53.9 46.5,
60.8
52.0 47.0,
60.2
51.8 46.7,
56.5
52.0 46.4,
57.0
Lower extremity, difference
from measurement at hospital
discharge (cm)
– – +0.5 −2.5,
+3.5
−1.3 −2.8,
+1.4
−2.2 −3.5,
+1.0
−2.7 −4.5,
+0.5
−2.7 −4.5,
+1.0
Measurements around the wrist/hand or ankle/foot [23-26]. Upper extremity measurements based on 10 subjects with upper extremity envenomation except for
the Day 7 and Day 14 measurements (n-9). Lower extremity measurements based on 10 subjects with lower extremity envenomation except for the Day 3
measurement (n = 9). Higher numbers indicate more swelling. The day of envenomation is Day 0.
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deal of limitation through Day 7 and little limitation by
21 days after envenomation.
Health-related quality of life (SF-36® v2, Acute version)
Table 11 and Figure 11A–F show the patients’ self-
reported quality of life. As expected, the SF-36® PCS
scores showed more change over the 28-day study
than the MCS scores. Subjects reported decrements in
physical quality of life for the first 2 weeks after en-
venomation, after which most subjects rated their
quality of life as similar to before the envenomation
occurred. The median time to return to baseline was
21 days (range: 7 to >28 days) for the PCS and
10.5 days (range: 7 to >28 days) for the MCS. At the
Day 28 assessment, 7/20 patients (35%) reported PCS
scores and 9/20 patients (45%) reported MCS scores that
were worse than their pre-envenomation baselines.
Work productivity and daily activity impairment (WPAI:
SHP, version 2)
Evaluation of responses to the Work Productivity Im-
pairment items on the WPAI: SHP instrument showed
uninterpretable results. Of the 20 study subjects, 7 re-
ported that they were not employed at any of the assess-
ment time points, and 2 additional subjects appeared to
have lost, gained, and/or regained employment during
the course of the study. Of the remaining 11 subjects,
we were unable to calculate a work productivity impair-
ment score at one or more time points for 4 subjects
due to missing responses or a sum of 0 scheduled work
hours [hours actually worked + hours missed due to snake-
bite + hours missed for other reasons]. Of the remaining 7
study subjects, 6 subjects provided data showing a sum of
scheduled work hours that varied more than 100% between
the assessments. Therefore, work productivity impairment
is not reported.
Table 12 and Figure 12A–C show impairment of daily
activities outside of work for all 20 subjects. The median
time to return to full participation in daily activities out-
side work was 21 days (range: 3 to >28 days), and 5/20
subjects (25%) reported less than full participation in
non-work activities 28 days after envenomation.
Objectively-measured swelling
Despite promising results from the use of figure-of-eight
measurements in other orthopedic conditions, these mea-
surements did not appear to track with other measures of
recovery (Table 13; Figure 13A–B). It is unclear whether
this is because swelling resolved prior to the Day 3 meas-
urement, swelling did not involve the wrist/hand or ankle/
foot, swelling was effectively managed by other means
(e.g. wrapping, elevation), or the measurements were not
consistent and accurate.
Figure 13 Figure-of-Eight Swelling Measurements: Subgroup Results. A: Upper Extremity. FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size:
FabAV n = 6; No FabAV n = 4. Missing data from one FabAV subject on Days 7 and 14. B: Lower Extremity. FabAV: Crotaline Polyvalent Immune Fab
(ovine). Subgroup size: FabAV n = 9; No FabAV n = 1. Missing data from one FabAV subject on Day 3.
Table 14 Grip strength: Overall Study Results
Discharge Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range Median Range
Strength (kg) 12 UTP, 40 33 2, 57 34 8, 62 38 11, 66 46 12, 70 40 18, 68
Number of subjects unable
to complete test
1/10 (10%) 0/10 (0%) 0/9 (0%) 0/9 (0%) 0/10 (0%) 0/10 (0%)
Grip strength, measured in kilograms [27,28]. UTP: Unable to perform test. Data from 10 subjects with upper extremity envenomation except for the Day 7 and
Day 14 measurements (n = 9). Higher numbers indicate more strength. The day of envenomation is Day 0.
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Objectively-measured function
Among patients bitten on the hand or forearm, median
grip strength increased 217% from the discharge to Day
14 assessments, then plateaued (Table 14; Figure 14A–B).
Most patients bitten on the leg or ankle could not walk
without assistance through at least the first three days after
injury. Most were walking well by Day 7. Because the only
mildly- envenomated subject in this study was bitten on
the arm, no mildly-envenomated subjects completed the
walking speed assessment (Table 15; Figure 15A–B).
Correlation between study measures
Table 16 provides data about the correlation between differ-
ent outcome measures at Day 14. Out of 62 comparisons,
55 had correlation coefficients in the expected direction
(i.e. both tests suggested improvement or worsening), and 6
of the 7 of the remaining correlations were weak (ρ < 0.15).
There was a moderate correlation (ρ = 0.65) between grip
strength and figure-of-8 swelling measurement of the wrist
that suggested the higher the grip strength the more
swelling. We theorize that this is due to the fact that
figure-of-8 measures both the patient’s size and super-
imposed swelling. Given that there was little change in
the figure-of-8 measurements over time and figure-of-8
measurements were very weakly correlated with self-
reported swelling (ρ = 0.08), the most likely explanation
is confounding based on the fact that larger patients
may be stronger than smaller patients.
The Patient-Specific Functional Scale and the WPAI:
SHP Daily Activities Impairment question were moderately
to highly correlated (ρ ≥ 0.6) with each other and with a
broad range of other study instruments. Two single-item
questions, the Numeric Pain Rating Scale and the Patient’s
Global Impression of Change, were moderately to highly
correlated with more complex methods of assessing limb
impairment, including the 30-item DASH and 12-item
LEFS instruments. The 11-item QuickDASH, a subset of
the DASH instrument, was highly correlated with the
DASH (Pearson’s correlation coefficient range 0.81 – 0.99
at different time points).
The best patient-reported instruments, such as PSFS,
DASH, and LEFS, had at least moderately strong correl-
ation (Spearman’s ρ 0.71 – 0.84) with the objective mea-
surements of function, grip strength and the ability to
walk 25 feet/7.62 meters without assistance.
In this study, several simple questions (PSFS, WPAI:
SHP Daily Activities impairment question, Numeric Pain
Rating Scale, Patient’s Global Impression of Change) and
objective tests (grip strength, 25 foot walking test) pro-
vided consistent information, suggesting that these parsi-
monious tools may be valid and practical ways to assess
limb recovery in snakebite victims.
Figure 14 Grip Strength: Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV n = 6; No FabAV n = 4. Missing
data from one FabAV subject on Days 7 and 14. B: Subgroup size: Mild n = 1; Moderate n = 8; Severe n = 1. Missing data from the Severe subject on Days
7 and 14.
Table 15 Walking speed: Overall Study Results
Discharge Day 3 Day 7 Day 14 Day 21 Day 28
Median Range Median Range Median Range Median Range Median Range Median Range
Time to walk 7.62 meters (sec) UTP 7.1, UTP UTP 6.8, UTP 6.7 4.9, UTP 6.2 4.1, 11.4 5.5 4.3, 7.2 5.3 4.0, 6.2
Number of subjects unable to
complete test
7/10 (70%) 6/9 (66%) 2/10 (20%) 0/10 (0%) 0/10 (0%) 0/10 (0%)
Time to walk 7.62 meters (25 feet) on indoor level ground, in seconds [29,30]. UTP: Unable to perform test (unable to safely walk 7.62 meters without assistance
devices in 180 seconds or less). Data from 10 subjects with lower extremity envenomations except for the Day 3 measurements (n = 9). Higher numbers indicate
slower ambulation. The maximum amount of time allowed for the task is 180 seconds, and subjects who were unable to complete the task were scored as 180 seconds. The
day of envenomation is Day 0.
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Safety
Ten adverse events (AEs) were reported by 7 subjects
during the time of subjects’ participation in the study
(from the time of consent through completion of the
Day 28 assessment.) None were rated as “serious” or
judged to be related to study participation.
Four patients (27% of those receiving FabAV) had a
total of 5 acute hypersensitivity reactions to FabAV.
Three of these reactions occurred prior to study enroll-
ment and 2 during study participation. One patient had
a medically significant reaction, consisting of wheezing,
dyspnea, hypotension, and rash, which began shortly
after the FabAV infusion rate was increased from
20 mL/hour to 250 mL/hour. FabAV was discontinued,
and the patient received oxygen, intravenous fluids,
methylprednisolone, diphenhydramine, and famotidine.
His blood pressure and respiratory distress improved,
as did the swelling in his envenomated limb. He was
discharged from the hospital two days later without in-
cident. Another subject had 2 distinct episodes of acute
hypersensitivity reaction to FabAV. This patient devel-
oped an urticarial rash during the initial FabAV infu-
sion which improved with diphenhydramine. She was
able to complete the initial FabAV dose without further
Figure 15 Walking Speed: Subgroup Results. A: FabAV: Crotaline Polyvalent Immune Fab (ovine). Subgroup size: FabAV n = 9; No FabAV n = 1. B:
Subgroup size: Mild n = 0, Moderate n = 8, Severe n = 2.
Table 16 Correlation between assessment items (Day 14 time point; absolute values shown)
Variable Walking
Speed
Grip
Strength
Figure- of-8
Swelling
PSFS WPAI:SHP Daily
Activities
Impairment
DASH LEFS PGIC NSS NPRS SF-36v2
MCS
SF-36v2
PCS
Walking Speed 1 n/a 0.66 0.72 0.76 n/a 0.71 0.84 0.25 0.75 0.42 0.64
Grip Strength – 1 0.65* 0.84 0.73 0.81 n/a 0.86 0.58 0.70 0.26 0.29
Figure-of-8 Swelling 1 0.06* 0.33 0.62 0.48 0.14* 0.08 0.08 0.37 0.08
PSFS 1 0.72 0.95 0.83 0.79 0.61 0.93 0.78 0.67
WPAI:SHP Daily Activities
Impairment
1 0.72 0.80 0.55 0.61 0.80 0.21 0.59
DASH 1 n/a 0.64 0.55 0.88 0.03* 0.73
LEFS 1 0.92 0.65 0.93 0.15 0.88
PGIC 1 0.43 0.68 0.01* 0.52
NSS 1 0.75 0.08* 0.47
NPRS 1 0.02 0.71
SF-36v2 MCS 1 0.12*
SF-36v2 PCS 1
PSFS: Patient-Specific Functional Scale score [18,19]; WPAI:SHP: Work Productivity and Ability Impairment: Special Health Problem instrument, version 2 [21]; DASH:
Disorders of the Arm, Shoulder, and Hand outcome measure [15,16]; PGIC: Patient’s Global Impression of Change, Scale 1 score [14]; LEFS: Lower Extremity Functional Scale
[17]; NSS: Numeric Swelling Scale; NPRS: Numeric Pain Rating Scale; SF-36® MCS and PCS: Mental and Physical Component Scores on the Medical Outcomes Study 36-item
Short Form Health Survey version 2 (SF-36®, v2) Acute Version instrument; n/a: not applicable; nd: no data or insufficient data to make this calculation. Because increasing
values indicate improvement in some outcome measures and decrement in others, absolute values for correlations are shown. Results of the PGIC Scale 2 score are similar to
the Scale 1 score (data not shown).
*Correlation is in the opposite direction from what is expected based on the design of the test (i.e. one test suggests worsening and the other suggests improvement).
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incident. Several hours later she received a second dose
of FabAV for progressive limb swelling, and experi-
enced recurrence of her rash. This responded well to
additional diphenhydramine, and she completed her
second dose of FabAV without difficulty. At no time
did she develop wheezing or hypotension, and her clin-
ical course was otherwise unremarkable. Two add-
itional subjects had mild urticarial reactions that
responded to antihistamine administration.
Discussion
Copperhead envenomation commonly causes pain and
swelling in the envenomated limb that interferes with the
patient’s quality of life and ability to function in work and
leisure activities. In this first study to examine the natural
history of this condition, patients typically had pain and
limitations lasting about 2 weeks after envenomation.
Most subjects, but not all, were fully recovered by 1 month
after envenomation. Recovery may have been slower for
patients with lower extremity envenomation.
A very simple patient-reported outcome measure, the
PSFS, was both highly correlated with more complex as-
sessment tools and very responsive to changes in patient
condition over time. The use of patient-reported outcome
measures has been advocated by the FDA and others as a
preferred way to assess outcomes in clinical trials [34].
Within the limitations of its size and design, this study sug-
gests that parsimonious and patient-centered tools are well-
suited to study recovery from snake envenomation. Two
easily-obtained measurements of function, grip strength
and the ability to walk 25 feet/7.62 meters without assist-
ance also performed well in this study.
This study is limited by its observational study design
and small sample size. In particular, 75% of the subjects
in this study received FabAV, and the patients managed
with FabAV tended to have a more severe envenom-
ation. Several factors, including small sample size and
the lack of a standardized assessment of severity at the
time a decision about FabAV administration was made,
precluded the use of propensity-adjustment, propensity-
matching, or stratified analytic methods to adjust for
confounding by indication. This study was designed to
be exploratory rather than hypothesis-testing; given the
lack of formal statistical testing for significant differences
or adjustment for multiple measures, no strong conclu-
sions about subgroups can be supported. This study can-
not be used to prove or disprove a clinical benefit
associated with FabAV administration.
The problem of small sample size is particularly im-
portant given the large variability observed in some mea-
sures and the fact that skewed and ordinal data required
the use of nonparametric statistical tests. These reasons
alone should cause the reader to interpret the specific
results with caution, as the estimate of effect for most
measures is imprecise. An additional important limita-
tion is that 60% of subjects came from a single institu-
tion, where both the local fauna and treatment resources
may produce different outcomes than experienced else-
where. If a difference in clinical disease spectrum is
present in envenomations by copperheads from different
subspecies (e.g. A. c. contortrix vs. A. c. mokasin) or re-
gions (e.g. North Carolina vs. Texas), the generalizability
of these results would be threatened.
Pain is an inherently subjective experience. In addition to
the numeric pain rating score, pain is directly assessed in
the DASH (2/30 items) and the SF-36 (2/36 items). Pain
also contributes to limitations in role function (measured in
the PSFS, DASH, LEFS, and WPAI: SHP), physical function
(grip strength, walking speed), quality of life (SF-36), and
analgesic use. To the extent that a subject’s perception of
pain is influenced by psychosocial factors, medical and
psychiatric comorbidities, prior medication and other
substance use, and personality, these instruments may
be measuring more than just the effects of venom on
human tissue. Acknowledging these limits, pain and its
effect on function are important, patient-centered out-
comes and are important to consider in this context.
Conclusions
In this population of patients envenomated by copperheads,
most of whom received antivenom, pain, swelling, and dis-
ability lasted 7 – 21 days in most patients. Several tools ap-
pear to be responsive and useful in studying recovery from
pit viper envenomation. These include the DASH, LEFS,
PSFS, SF-36® PCS, WPAI: SHP Daily Activities Impairment
component, and structured self-reports of pain, swelling,
analgesic use, recovery, and return to usual activities.
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